The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by Morgan Stanley on March 26, 2026. The analyst firm set a price target for $42.00 expecting DNLI to rise to within 12 months (a possible 118.81% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by Morgan Stanley, and Denali Therapeutics maintained their overweight rating.

The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.

There is no last downgrade for Denali Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on March 26, 2026 so you should expect the next rating to be made available sometime around March 26, 2027.

While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $40.00 to $42.00. The current price Denali Therapeutics (DNLI) is trading at is $19.20, which is out of the analyst’s predicted range.